Edition:
United Kingdom

Ovid Therapeutics Inc (OVID.OQ)

OVID.OQ on NASDAQ Stock Exchange Global Select Market

8.96USD
17 May 2018
Change (% chg)

-- (--)
Prev Close
$8.96
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
27,090
52-wk High
$15.70
52-wk Low
$5.28

Revenue & Earnings Per Share

    Revenue* Earnings Per Share**
FY 2018 Mar '18 0.00 -0.536
FY 2017 Dec '17 0.00 -0.057
Sep '17 0.00 -0.380
Jun '17 0.00 -0.566
Mar '17 0.00 -1.392
FY 2016 Dec '16 0.00 -0.307
Sep '16 0.00 -0.235
Jun '16 0.00 -0.219
Mar '16 0.00 -0.150
 
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars

Consensus Estimates Analysis

  # of Estimates Mean High Low 1 Year Ago
SALES (in millions)
Quarter Ending Jun-18 4 0.00 0.00 0.00 --
Quarter Ending Sep-18 4 0.00 0.00 0.00 --
Year Ending Dec-18 4 0.00 0.00 0.00 --
Year Ending Dec-19 5 0.00 0.00 0.00 --
Earnings (per share)
Quarter Ending Jun-18 5 -0.60 -0.52 -0.68 --
Quarter Ending Sep-18 5 -0.68 -0.53 -0.96 --
Year Ending Dec-18 5 -2.48 -2.15 -2.98 --
Year Ending Dec-19 6 -2.81 -2.27 -4.05 --
Sales and Profit Figures in US Dollar (USD);

Valuation Ratios

  Company industry sector
P/E Ratio (TTM) -- 84.06 32.75
P/E High - Last 5 Yrs. -- 293.32 45.73
P/E Low - Last 5 Yrs. -- 91.63 24.23
Beta -- 0.90 0.88
Price to Sales (TTM) -- 110.95 5.71
Price to Book (MRQ) 2.04 13.58 5.37
Price to Tangible Book (MRQ) 2.04 14.04 6.94
Price to Cash Flow (TTM) -- 71.44 23.33
% Owned Institutions 35.96 12.71 2.16

Dividends

  Company industry sector
Dividend Yield -- 0.31 1.50
Dividend Yield - 5 Year Avg -- 0.26 1.51
Dividend 5 Year Growth Rate -- 1.66 5.32
Payout Ratio(TTM) -- 15.72 43.29

Growth Rates

  Company industry sector
Sales (MRQ) vs Qtr. 1 Yr. Ago -- 399.27 9.21
Sales (TTM) vs TTM 1 Yr. Ago -- 78.86 5.69
Sales - 5 Yr. Growth Rate -- 32.18 10.32
EPS (MRQ) vs Qtr. 1 Yr. Ago -- 25.14 19.38
EPS (TTM) vs TTM 1 Yr. Ago -- -- --
EPS - 5 Yr. Growth Rate -- 39.01 10.77
Capital Spending - 5 Yr. Growth Rate -- 40.31 15.47

Financial Strength

  Company industry sector
Quick Ratio (MRQ) -- 1.81 2.19
Current Ratio (MRQ) 15.19 5.29 2.98
LT Debt to Equity (MRQ) 0.00 22.98 12.17
Total Debt to Equity (MRQ) 0.00 24.63 16.44
Interest Coverage (TTM) -- -99.39 32.81

Profitability Ratios

  Company industry sector
Gross Margin (TTM) -- 40.04 54.45
Gross Margin - 5 Yr. Avg. -- 51.16 52.21
EBITD Margin (TTM) -- -- --
EBITD - 5 Yr. Avg -- -575.09 10.96
Operating Margin (TTM) -- -718.94 4.73
Operating Margin - 5 Yr. Avg. -- -596.41 6.40
Pre-Tax Margin (TTM) -- -693.40 5.57
Pre-Tax Margin - 5 Yr. Avg. -- -599.76 6.82
Net Profit Margin (TTM) -- -694.62 1.87
Net Profit Margin - 5 Yr. Avg. -- -602.62 3.09
Effective Tax Rate (TTM) -- 22.63 23.04
Effective Tax Rate - 5 Yr. Avg. -- 18.22 23.95

Efficiency

  Company industry sector
Revenue/Employee (TTM) -- 22,637,573 847,034,055
Net Income/Employee (TTM) -- 2,973,815 99,640,144
Receivable Turnover (TTM) -- 20.17 5.78
Inventory Turnover (TTM) -- 2.37 3.35
Asset Turnover (TTM) -- 0.39 0.92

Management Effectiveness

  Company industry sector
Return on Assets (TTM) -- -1.09 10.95
Return on Assets - 5 Yr. Avg. -- -0.58 12.32
Return on Investment (TTM) -- 1.57 14.38
Return on Investment - 5 Yr. Avg. -- 2.21 16.11
Return on Equity (TTM) -- 2.43 16.07
Return on Equity - 5 Yr. Avg. -- 3.09 17.39
  1 Year 3 Year 5 Year
Sales % -- -- --
EPS (TTM) % -70.32 -- --
Dividend % -- -- --
Note: Units in Millions of US Dollars

Performance for Ovid Therapeutics Inc

Period %
Actual
% vs.
S&P 500
Rank In
Industry
Industry
Rank
4 Week 2.95 -0.60 53 53
13 Week -13.70 -17.90 27 65
26 Week -- -- -- 77
52 Week -- -- -- 50
YTD -- -- -- 58
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.

Institutional Holders

% Shares Owned: 29.62%
# of Holders: 69
Total Shares Held: 7,292,903
3 Mo. Net Change: -770,522
# New Positions: 11
# Closed Positions: 11
# Increased Positions: 50
# Reduced Positions: 20
# Net Buyers: 30
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.